33918041|t|Current Management and Therapeutic Strategies for Cerebral Amyloid Angiopathy.
33918041|a|Cerebral amyloid angiopathy (CAA) is characterized by accumulation of amyloid beta (Abeta) in walls of leptomeningeal vessels and cortical capillaries in the brain. The loss of integrity of these vessels caused by cerebrovascular Abeta deposits results in fragile vessels and lobar intracerebral hemorrhages. CAA also manifests with progressive cognitive impairment or transient focal neurological symptoms. Although development of therapeutics for CAA is urgently needed, the pathogenesis of CAA remains to be fully elucidated. In this review, we summarize the epidemiology, pathology, clinical and radiological features, and perspectives for future research directions in CAA therapeutics. Recent advances in mass spectrometric methodology combined with vascular isolation techniques have aided understanding of the cerebrovascular proteome. In this paper, we describe several potential key CAA-associated molecules that have been identified by proteomic analyses (apolipoprotein E, clusterin, SRPX1 (sushi repeat-containing protein X-linked 1), TIMP3 (tissue inhibitor of metalloproteinases 3), and HTRA1 (HtrA serine peptidase 1)), and their pivotal roles in Abeta cytotoxicity, Abeta fibril formation, and vessel wall remodeling. Understanding the interactions between cerebrovascular Abeta deposits and molecules that accumulate with Abeta may lead to discovery of effective CAA therapeutics and to the identification of biomarkers for early diagnosis.
33918041	50	77	Cerebral Amyloid Angiopathy	Disease	MESH:D016657
33918041	79	106	Cerebral amyloid angiopathy	Disease	MESH:D016657
33918041	108	111	CAA	Disease	MESH:D016657
33918041	149	161	amyloid beta	Gene	351
33918041	163	168	Abeta	Gene	351
33918041	309	314	Abeta	Gene	351
33918041	361	386	intracerebral hemorrhages	Disease	MESH:D002543
33918041	388	391	CAA	Disease	MESH:D016657
33918041	424	444	cognitive impairment	Disease	MESH:D003072
33918041	464	485	neurological symptoms	Disease	MESH:D009461
33918041	528	531	CAA	Disease	MESH:D016657
33918041	572	575	CAA	Disease	MESH:D016657
33918041	753	756	CAA	Disease	MESH:D016657
33918041	972	975	CAA	Disease	MESH:D016657
33918041	1046	1062	apolipoprotein E	Gene	348
33918041	1064	1073	clusterin	Gene	1191
33918041	1075	1080	SRPX1	Gene	8406
33918041	1082	1124	sushi repeat-containing protein X-linked 1	Gene	8406
33918041	1127	1132	TIMP3	Gene	7078
33918041	1134	1174	tissue inhibitor of metalloproteinases 3	Gene	7078
33918041	1181	1186	HTRA1	Gene	5654
33918041	1188	1211	HtrA serine peptidase 1	Gene	5654
33918041	1242	1247	Abeta	Gene	351
33918041	1262	1267	Abeta	Gene	351
33918041	1369	1374	Abeta	Gene	351
33918041	1419	1424	Abeta	Gene	351
33918041	1460	1463	CAA	Disease	MESH:D016657
33918041	Association	351	5654
33918041	Association	MESH:D002543	351
33918041	Association	MESH:D016657	1191
33918041	Association	MESH:D016657	5654
33918041	Association	MESH:D016657	8406
33918041	Association	351	8406
33918041	Association	MESH:D016657	7078
33918041	Association	351	7078
33918041	Association	MESH:D016657	351
33918041	Association	MESH:D016657	348

